share_log

雲白國際：截至二零二三年十二月三十一日止九個月之末期業績

YNBY INTL: FINAL RESULTS FOR THE NINE MONTHS ENDED 31 DECEMBER 2023

香港交易所 ·  Mar 22 09:06
Summary by Moomoo AI
雲白國際有限公司（「雲白國際」）公佈截至2023年12月31日止九個月的末期業績。該公司及其附屬公司（「集團」）在此期間的收益為約578.74億港元，較上一財政年度的約452.91億港元增加。毛利從約22.91億港元增至約49.60億港元。期內溢利為約143.73億港元，而上一財政年度為虧損約168.86億港元。每股基本盈利為2.11港仙，而上一財政年度每股基本及攤薄虧損為2.51港仙。集團的主要業務為投資控股，主要從事貨品及商品貿易業務。報告期內，集團未派發任何股息。雲白國際的股份於香港聯合交易所有限公司主板上市，雲南白藥集團為其控股股東。
雲白國際有限公司（「雲白國際」）公佈截至2023年12月31日止九個月的末期業績。該公司及其附屬公司（「集團」）在此期間的收益為約578.74億港元，較上一財政年度的約452.91億港元增加。毛利從約22.91億港元增至約49.60億港元。期內溢利為約143.73億港元，而上一財政年度為虧損約168.86億港元。每股基本盈利為2.11港仙，而上一財政年度每股基本及攤薄虧損為2.51港仙。集團的主要業務為投資控股，主要從事貨品及商品貿易業務。報告期內，集團未派發任何股息。雲白國際的股份於香港聯合交易所有限公司主板上市，雲南白藥集團為其控股股東。
Yunbai International Limited (“Yunbai International”) announces final results for the nine months ended 31 December 2023. The Company and its subsidiaries (the “Group”) generated revenues during this period of approximately HK$578.74 million, an increase from approximately HK$452.91 million in the previous fiscal year. Gross profit increased from approximately HK$22.91 million to approximately HK$49.60 billion. Profit for the period was approximately HK$143.73 million, compared to a loss of HK$168.86 million in the previous financial year. Basic earnings per share were HK$2.11 cents, compared to basic and diluted loss per share of HK$2.51 cents in the previous fiscal year. The Group's main business is investment holdings, primarily engaged in commodity and commodity trading. During the reporting period, the Group did not pay any dividends. Yunbai International's shares are listed on the main board of the Hong Kong Stock Exchange Limited, with Yunnan Biopharmaceuticals Group as its controlling shareholder.
Yunbai International Limited (“Yunbai International”) announces final results for the nine months ended 31 December 2023. The Company and its subsidiaries (the “Group”) generated revenues during this period of approximately HK$578.74 million, an increase from approximately HK$452.91 million in the previous fiscal year. Gross profit increased from approximately HK$22.91 million to approximately HK$49.60 billion. Profit for the period was approximately HK$143.73 million, compared to a loss of HK$168.86 million in the previous financial year. Basic earnings per share were HK$2.11 cents, compared to basic and diluted loss per share of HK$2.51 cents in the previous fiscal year. The Group's main business is investment holdings, primarily engaged in commodity and commodity trading. During the reporting period, the Group did not pay any dividends. Yunbai International's shares are listed on the main board of the Hong Kong Stock Exchange Limited, with Yunnan Biopharmaceuticals Group as its controlling shareholder.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more